Biogen
(NASDAQ:BIIB)
$190.52
-1.64[-0.85%]
At close: Apr 18
$190.52
0[0.00%]
After Hours: 4:00PM EDT
Q1 2024 Earnings in 6 days from now on Wed Apr 24th, before the market open
Conference call scheduled in 6 days at 8:30 AM Click to view the webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
50%
Overview Rating
Speculative
Technicals Analysis
66
0100
Financials Analysis
40
0100

Biogen Stock (NASDAQ:BIIB), Quotes and News Summary

Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.

Open$191.750
Close$190.520
Volume / Avg.1.512M / 1.179M
Day Range189.520 - 192.560
52 Wk Range192.010 - 334.580
Market Cap$27.694B
P/E Ratio24.103
Dividend Yield-
ExchangeNASDAQ
RSI
23
Short Interest
2.76%
Days to Cover2.85

Recent News

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Vandana Singh
Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers
February labor report shows mixed signals: increase in non-farm payrolls but higher unemployment rate and downward revisions. Wage growth lower than expected, fueling bets on Fed rate cuts. Stocks react with slight increase, top gainers include Atlassian, JM Smucker, GFL Environmental.
Piero Cingari
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA action beyond Q1 2024.
Vandana Singh
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
4
Dec 23
1
2
Jan
11
2
Feb
2
Mar
5
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Biogen Inc
Sector
Health Care
Industry
Biotechnology
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex a...
Show More

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
BIIB
LEGN

FAQ

Q

How do I buy Biogen (BIIB) stock?

A

You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Biogen's (BIIB) competitors?

A

Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ: BIIB) was reported by UBS on Wednesday, April 17, 2024. The analyst firm set a price target for 214.00 expecting BIIB to rise to within 12 months (a possible 12.32% upside). 85 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biogen (BIIB)?

A

The stock price for Biogen (NASDAQ: BIIB) is $190.52 last updated Today at April 18, 2024 at 4:00 PM EDT.

Q

Does Biogen (BIIB) pay a dividend?

A

There are no upcoming dividends for Biogen.

Q

When is Biogen (NASDAQ:BIIB) reporting earnings?

A

Biogen’s Q1 earnings are confirmed for Wednesday, April 24, 2024.

Q

Is Biogen (BIIB) going to split?

A

There is no upcoming split for Biogen.

Q

What sector and industry does Biogen (BIIB) operate in?

A

Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch